Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10X Genomics Faces Financial Risks Amid Challenges in Data Interpretation and Customer Support
- 10X Genomics Earnings Call: Innovations Amidst Revenue Challenges
- Positive Outlook for 10x Genomics Amid Strong Financials and Growth Prospects
- 10x Genomics price target lowered to $15 from $18 at TD Cowen
- 10x Genomics price target lowered to $16 from $20 at BofA